Archive for the ‘blood (journal) retractions’ Category
Blood has retracted two 2013 illustrations of red cells by researchers from South Africa and the United States because, somewhat confusingly, they didn’t conform to the journal’s criteria for publishing such material.
A stem cell journal is retracting a paper by Gerold Feuer, a researcher at the State University of New York (SUNY) Upstate Medical Center in Syracuse who was also found to have misused grants.
The Feuer story is complicated. Heralded in 2008 for landing $6.2 million in grants from the New York Stem Cell Board, Feuer was suspended in October 2010 while the university investigated allegations he had misused funds, specifically to funnel state dollars to HuMurine, a company he founded in 2008. In December 2010, Upstate said they had found evidence he had committed 53 acts of financial misconduct, and dismissed him.
Two Expressions of Concern in Blood for MD Anderson’s Aggarwal, who has threatened to sue Retraction Watch
Bharat Aggarwal, the MD Anderson researcher who has threatened to sue us while under investigation by his institution for alleged misconduct, now has two Expressions of Concern in addition to two corrections and two unexplained withdrawals.
Both of the papers were published in Blood. The Expression of Concern for “Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway,” reads: Read the rest of this entry »
A case of alleged misconduct at the University of Washington in Seattle may finally be over. The Office of Research Integrity released its findings following an investigation into the work of Andrew Aprikyan, a former hematology researcher at the university.
The Aprikyan case has dragged on for a decade. In 2010, the university fired the scientist after a court denied his appeals based on allegations that they had denied him due process. As the Seattle Times reported at the time: Read the rest of this entry »
We’ve been following the case of Kenji Okajima, a professor at Nagoya City University in Japan who was suspended for six months following an investigation into work in his lab. Bits of the story — including at least one other university investigation, and scrutiny of Okajima’s colleagues, one of whom was fired — have been dribbling out for almost two years since a retraction notice in the Journal of Neuroscience.
In all, it looks as Nagoya found evidence of misconduct in 19 papers. The Journal of Neuroscience retraction appeared in 2011, and another showed up in the Journal of Immunology last year. Now there are three more: One in Translational Research and two in Blood.
Shane Mayack, a former post-doc in Harvard lab of Amy Wagers, a rising star in the stem cell field, has been sanctioned by the Office of Research Integrity for misconduct.
Mayack, who has defended her actions on this blog as honest error — albeit sloppiness — and has not admitted to wrongdoing, must undergo supervision if she receives any federal grant funding over the next three years, under the voluntary agreement.
The group’s work became the focus of expressions of concern from the Journal of Clinical Oncology this spring and in 2010.
The article, “Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia,” purported to show “a role of abnormal Wnt signaling in ALL and establish a group of patients with a significantly worse prognosis (methylated group)” and earned a commentary on the significance of the findings.
We have an update on the case of a University of Utah lab that retracted two Cell Metabolism papers last month after a fired lab technician disposed of two lab notebooks without permission. The team has now corrected two other papers, one in Blood and the other in the Journal of Clinical Investigation.
The authors of a paper published last September in Blood about alleged links between certain genes and Hodgkin’s lymphoma have retracted it, after realizing they’d made mistakes in their calculations.
The retraction notice for “Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups,” dated January 20 and signed by all of the authors, clearly explains what went wrong, taking pains to note that there was no misconduct involved: Read the rest of this entry »